Skip to main content
Top
Published in: Rheumatology International 1/2007

01-11-2007 | Review

Elderly-onset gout: a review

Authors: Francesco De Leonardis, Marcello Govoni, Matteo Colina, Marco Bruschi, Francesco Trotta

Published in: Rheumatology International | Issue 1/2007

Login to get access

Abstract

Elderly-onset gout (EOG), defined as a disease with onset at age 65 years or over, shows relevant epidemiological, clinical and therapeutic differences from the typical middle-age form. The main differences are the more frequent subacute/chronic polyarticular onset with hand involvement, the unusual localization of tophi on ostheoarthritis (OA) nodes, the increased female/male ratio and the frequent association with drugs that decrease renal urate excretion (diuretics and low-dose aspirin) and/or with primitive renal impairment. EOG has recently been confirmed as the most common inflammatory arthropathy in older people, with important demographic implications and substantial impact on daily clinical practice. Despite the high prevalence, gout, in the elderly, often remains misdiagnosed or diagnosed late in its clinical course. Even when correctly recognized, its treatment is often difficult or unsatisfactory.
Literature
1.
go back to reference Ene-Stroescu D, Gorbien MJ (2005) Gouty arthritis. A primer on late-onset gout. Geriatrics 60:24–31PubMed Ene-Stroescu D, Gorbien MJ (2005) Gouty arthritis. A primer on late-onset gout. Geriatrics 60:24–31PubMed
2.
go back to reference Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG (2005) Gout epidemiology: results from the UK general practice research database, 1990–1999. Ann Rheum Dis 64:267–272CrossRefPubMed Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG (2005) Gout epidemiology: results from the UK general practice research database, 1990–1999. Ann Rheum Dis 64:267–272CrossRefPubMed
3.
go back to reference Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41:778–799CrossRefPubMed Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41:778–799CrossRefPubMed
4.
go back to reference Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R (2004) Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 31:1582–1587PubMed Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R (2004) Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 31:1582–1587PubMed
5.
go back to reference Arromdee E, Michet JC, Crowson CS, O’Fallon WM, Gabriel S (2002) Epidemiology of gout: is the incidence rising? J Rheumatol 29:2403–2406PubMed Arromdee E, Michet JC, Crowson CS, O’Fallon WM, Gabriel S (2002) Epidemiology of gout: is the incidence rising? J Rheumatol 29:2403–2406PubMed
6.
go back to reference Kim KY, Schumacher RH, Hunsche E, Wertheimer AI, Kong SX (2003) A literature review of the epidemiology and treatment of acute gout. Clin Ther 25:1593–1617CrossRefPubMed Kim KY, Schumacher RH, Hunsche E, Wertheimer AI, Kong SX (2003) A literature review of the epidemiology and treatment of acute gout. Clin Ther 25:1593–1617CrossRefPubMed
7.
go back to reference Harrold LR, Yood R, Milkus TR, Andrade S, Davis J, Fuller K, Chan A, Roblin D, Raebel M, Von Worley A, Platt R, Saag K (2006) Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis 65:1368–1372CrossRefPubMed Harrold LR, Yood R, Milkus TR, Andrade S, Davis J, Fuller K, Chan A, Roblin D, Raebel M, Von Worley A, Platt R, Saag K (2006) Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis 65:1368–1372CrossRefPubMed
8.
go back to reference De Souza AW, Fernandes V, Ferrari AJ (2005) Female gout: clinical and laboratory features. J Rheumatol 32:2186–2188PubMed De Souza AW, Fernandes V, Ferrari AJ (2005) Female gout: clinical and laboratory features. J Rheumatol 32:2186–2188PubMed
9.
go back to reference Effectiveness of interventions for the treatment of acute and prevention of recurrent gout––a systematic review. Rheumatology 2006;45:1422–1431 Effectiveness of interventions for the treatment of acute and prevention of recurrent gout––a systematic review. Rheumatology 2006;45:1422–1431
10.
go back to reference Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med 1975;59:605–613 Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med 1975;59:605–613
11.
go back to reference Ter Borg EJ, Rasker JJ (1987) Gout in the elderly, a separate entity? Ann Rheum Dis 46:72–76PubMed Ter Borg EJ, Rasker JJ (1987) Gout in the elderly, a separate entity? Ann Rheum Dis 46:72–76PubMed
12.
go back to reference MacFarlane DG, Dieppe PA (1985) Diuretic-induced gout in elderly women. Br J Rheumatol 24:155–157CrossRefPubMed MacFarlane DG, Dieppe PA (1985) Diuretic-induced gout in elderly women. Br J Rheumatol 24:155–157CrossRefPubMed
13.
go back to reference Puig JG, Michan AD, Jimenez ML, Perez de Ayala C, Mateos FA, Capitan CF, de Miguel E, Gijon JB (1991) Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med 151:726–732CrossRefPubMed Puig JG, Michan AD, Jimenez ML, Perez de Ayala C, Mateos FA, Capitan CF, de Miguel E, Gijon JB (1991) Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med 151:726–732CrossRefPubMed
14.
go back to reference Gurwitz JH, Kalish SC, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J (1997) Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol 50:953–959CrossRefPubMed Gurwitz JH, Kalish SC, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J (1997) Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol 50:953–959CrossRefPubMed
15.
go back to reference Hunter DJ, York M, Chaisson CE, Woods R, Niu J, Zhang Y (2006) Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol 33:1341–1344PubMed Hunter DJ, York M, Chaisson CE, Woods R, Niu J, Zhang Y (2006) Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol 33:1341–1344PubMed
16.
go back to reference Scott JT, Higgen CS (1992) Diuretic induced gout: a multifactorial condition. Ann Rheum Dis 51:259–261PubMed Scott JT, Higgen CS (1992) Diuretic induced gout: a multifactorial condition. Ann Rheum Dis 51:259–261PubMed
17.
go back to reference Janssens HJEM, van de Linsdonk EH, Janssen M, van den Hoogen HJM, Verbeek ALM (2006) Gout, not induced by diuretics? A case-control study from primary care. Ann Rheum Dis 65:1080–1083CrossRefPubMed Janssens HJEM, van de Linsdonk EH, Janssen M, van den Hoogen HJM, Verbeek ALM (2006) Gout, not induced by diuretics? A case-control study from primary care. Ann Rheum Dis 65:1080–1083CrossRefPubMed
18.
go back to reference Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality. The NHANES 1 epidemiologic follow-up study, 1971–1992. JAMA 283:2404–2410CrossRefPubMed Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality. The NHANES 1 epidemiologic follow-up study, 1971–1992. JAMA 283:2404–2410CrossRefPubMed
19.
go back to reference Culleton BF, et al (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham heart study. Ann Int Med 131:7–13PubMed Culleton BF, et al (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham heart study. Ann Int Med 131:7–13PubMed
20.
go back to reference Hall AP, Barry PE, Dawber TR, McNamara PM (1967) Epidemiology of gout and hyperuricemia: a long term population study. Am J Med 42:27–37CrossRefPubMed Hall AP, Barry PE, Dawber TR, McNamara PM (1967) Epidemiology of gout and hyperuricemia: a long term population study. Am J Med 42:27–37CrossRefPubMed
21.
go back to reference Chen SY, Chen CL, Shen ML (2007) Manifestations of metabolic syndrome associated with male gout in different age strata. Clin Rheumatol January 26. doi:10.1007/s10067-006-0527-4 (in press) Chen SY, Chen CL, Shen ML (2007) Manifestations of metabolic syndrome associated with male gout in different age strata. Clin Rheumatol January 26. doi:10.​1007/​s10067-006-0527-4 (in press)
22.
go back to reference Krishnan E, Baker JF, Furst DE, Schumacher HR (2006) Gout and the risk of acute myocardial infarction. Arthitis Rheum 8:2688–2696CrossRef Krishnan E, Baker JF, Furst DE, Schumacher HR (2006) Gout and the risk of acute myocardial infarction. Arthitis Rheum 8:2688–2696CrossRef
23.
go back to reference Wernick R, Winkler C, Campbell S (1992) Tophi as the initial manifestation of gout. Report of six cases and review of the literature. Arch Intern Med 152:873–876CrossRefPubMed Wernick R, Winkler C, Campbell S (1992) Tophi as the initial manifestation of gout. Report of six cases and review of the literature. Arch Intern Med 152:873–876CrossRefPubMed
24.
go back to reference Doherty M, Dieppe P (1986) Crystal deposition disease in the elderly. Clin Rheum Dis 2:97–116 Doherty M, Dieppe P (1986) Crystal deposition disease in the elderly. Clin Rheum Dis 2:97–116
25.
go back to reference Foldes K, Petersilge CA, Weisman MH, Resnick D (1996) Nodal ostheoarthritis and gout: a report of four new cases. Skeletal Radiol 25:421–424CrossRefPubMed Foldes K, Petersilge CA, Weisman MH, Resnick D (1996) Nodal ostheoarthritis and gout: a report of four new cases. Skeletal Radiol 25:421–424CrossRefPubMed
26.
27.
go back to reference Gerster JC, Landry M, Dufresne L, Meuwly JY (2002) Imaging of tophaceus gout: computed tomography provides specific images compared with magnetic resonance imaging and ultrasonography. Ann Rheum Dis 61:52–54CrossRefPubMed Gerster JC, Landry M, Dufresne L, Meuwly JY (2002) Imaging of tophaceus gout: computed tomography provides specific images compared with magnetic resonance imaging and ultrasonography. Ann Rheum Dis 61:52–54CrossRefPubMed
28.
go back to reference Lopez Redondo MJ, Requena L, Macia M, Schoendorff C, Sanchez Yus E, Robledo A (1993) Fingertip tophi without gouty arthritis. Dermatology 187:140–143PubMedCrossRef Lopez Redondo MJ, Requena L, Macia M, Schoendorff C, Sanchez Yus E, Robledo A (1993) Fingertip tophi without gouty arthritis. Dermatology 187:140–143PubMedCrossRef
29.
go back to reference Chopra KF, Schneiderman P, Grossman ME (1999) Finger pad tophi. Cutis 64:233–236PubMed Chopra KF, Schneiderman P, Grossman ME (1999) Finger pad tophi. Cutis 64:233–236PubMed
30.
go back to reference Bomalaski JS, Schumacher HR (1984) Podagra is more than gout. Bull Rheum Dis 34:1–8PubMed Bomalaski JS, Schumacher HR (1984) Podagra is more than gout. Bull Rheum Dis 34:1–8PubMed
31.
go back to reference Kozin F, McCarty DJ (1977) Rheumatoid factors in the serum of gouty patients (letter). Arthritis Rheum 20:1559–1560CrossRefPubMed Kozin F, McCarty DJ (1977) Rheumatoid factors in the serum of gouty patients (letter). Arthritis Rheum 20:1559–1560CrossRefPubMed
32.
go back to reference Zhang W, Doherty M, Pascal E, Bardin T, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I (2006) Eular evidence based recommendations for gout––part I. Diagnosis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1301–1311CrossRefPubMed Zhang W, Doherty M, Pascal E, Bardin T, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I (2006) Eular evidence based recommendations for gout––part I. Diagnosis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1301–1311CrossRefPubMed
33.
go back to reference Zhang W, Doherty M, Pascal E, Bardin T, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I (2006) Eular evidence based recommendations for gout––part II. Management: report of task force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis 55:1312–1324CrossRef Zhang W, Doherty M, Pascal E, Bardin T, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I (2006) Eular evidence based recommendations for gout––part II. Management: report of task force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis 55:1312–1324CrossRef
34.
go back to reference Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated crystals activate the NALP3 inflammasome. Nature 440:237–241CrossRefPubMed Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated crystals activate the NALP3 inflammasome. Nature 440:237–241CrossRefPubMed
35.
go back to reference Chun CJ, Shi Y, Hearn A, Fitzgerald K, Golenbock D, Reed G, Akira S, Rock KL (2006) My D88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 116:2262–2271CrossRef Chun CJ, Shi Y, Hearn A, Fitzgerald K, Golenbock D, Reed G, Akira S, Rock KL (2006) My D88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 116:2262–2271CrossRef
36.
go back to reference Spilberg I, Mandell B, Mehta J, Simchowitz L, Rosenberg D (1979) Mechanism of action of colchicine in acute urate crystal-induced arthritis. J Clin Invest 64:775–780PubMedCrossRef Spilberg I, Mandell B, Mehta J, Simchowitz L, Rosenberg D (1979) Mechanism of action of colchicine in acute urate crystal-induced arthritis. J Clin Invest 64:775–780PubMedCrossRef
37.
go back to reference Roberge CJ, Gaudry M, de Medicis R, Lussier A, Poubelle PE, Naccache PH (1993) Crystal-induced neutrophil activation. IV. Specific inhibition of tyrosine phosphorylation by colchicine. J Clin Invest 92:1722–1729PubMed Roberge CJ, Gaudry M, de Medicis R, Lussier A, Poubelle PE, Naccache PH (1993) Crystal-induced neutrophil activation. IV. Specific inhibition of tyrosine phosphorylation by colchicine. J Clin Invest 92:1722–1729PubMed
38.
go back to reference Wilbur K, Makowsky M (2004) Colchicine myotoxicity: case reports and literature review. Pharmacotherapy 24:1784–1792CrossRefPubMed Wilbur K, Makowsky M (2004) Colchicine myotoxicity: case reports and literature review. Pharmacotherapy 24:1784–1792CrossRefPubMed
39.
go back to reference Groff GD, Franck WA, Raddatz DA (1990) Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 19:329–336CrossRefPubMed Groff GD, Franck WA, Raddatz DA (1990) Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 19:329–336CrossRefPubMed
40.
go back to reference Fernandez C, Noguera R, Gonzalez JA, Pascual E (1999) Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 26:2285–2286PubMed Fernandez C, Noguera R, Gonzalez JA, Pascual E (1999) Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 26:2285–2286PubMed
41.
go back to reference Arellano F, Sacristan JA (1993) Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 27:337–343PubMed Arellano F, Sacristan JA (1993) Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 27:337–343PubMed
42.
go back to reference Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76:47–56CrossRefPubMed Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76:47–56CrossRefPubMed
43.
go back to reference Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N (2005) Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. Arthritis Rheum 52:916–923CrossRefPubMed Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N (2005) Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. Arthritis Rheum 52:916–923CrossRefPubMed
44.
go back to reference Schumacher H, Becker M, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N (2005) Febuxostat vs allopurinol and placebo in subjects with hyperuricemia and gout: the 28-week APEX study. Arthritis Rheum 52:S680 Schumacher H, Becker M, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N (2005) Febuxostat vs allopurinol and placebo in subjects with hyperuricemia and gout: the 28-week APEX study. Arthritis Rheum 52:S680
45.
go back to reference Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS (2006) Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Care 8:R12CrossRef Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS (2006) Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Care 8:R12CrossRef
46.
go back to reference Schumacher HR Jr, Chen LX (2006) Newer therapeutic approaches: gout. Rheum Clin Dis North Am 32:235–244CrossRef Schumacher HR Jr, Chen LX (2006) Newer therapeutic approaches: gout. Rheum Clin Dis North Am 32:235–244CrossRef
47.
go back to reference Hoskison TK, Wortmann RL (2006) Advances in the management of gout and hyperuricemia. Scand J Rheumatol 35:251–260CrossRefPubMed Hoskison TK, Wortmann RL (2006) Advances in the management of gout and hyperuricemia. Scand J Rheumatol 35:251–260CrossRefPubMed
48.
go back to reference Puig JG, Mateos F, Buno A, Ortega R, Rodriguez F, Dal-Re R (1999) Effect of eprosartan and losartan on metabolism in patients with essential hypertension. J Hypertens 17:1033–1039CrossRefPubMed Puig JG, Mateos F, Buno A, Ortega R, Rodriguez F, Dal-Re R (1999) Effect of eprosartan and losartan on metabolism in patients with essential hypertension. J Hypertens 17:1033–1039CrossRefPubMed
49.
go back to reference Wurzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, Burnier M (2001) Comparative effects of losartan and irbesartan on serum in hypertensive patients with hyperuricaemia and gout. J Hypertens 19:1855–1860CrossRefPubMed Wurzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, Burnier M (2001) Comparative effects of losartan and irbesartan on serum in hypertensive patients with hyperuricaemia and gout. J Hypertens 19:1855–1860CrossRefPubMed
50.
go back to reference Schmidt A, Gruber U, Bohmig G, Koller E, Mayer G (2001) The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant 16:1034–1037CrossRefPubMed Schmidt A, Gruber U, Bohmig G, Koller E, Mayer G (2001) The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant 16:1034–1037CrossRefPubMed
51.
go back to reference Bastow MD, Durrington PN, Ishola M (1988) Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism 37:217–220CrossRefPubMed Bastow MD, Durrington PN, Ishola M (1988) Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism 37:217–220CrossRefPubMed
52.
go back to reference Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350:1093–1103CrossRefPubMed Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350:1093–1103CrossRefPubMed
53.
go back to reference Choi HK, Liu S, Curhan G (2005) Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the third national health and nutrition examination survey. Arthritis Rheum 52:283–289CrossRefPubMed Choi HK, Liu S, Curhan G (2005) Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the third national health and nutrition examination survey. Arthritis Rheum 52:283–289CrossRefPubMed
54.
go back to reference Lee SJ, Terkeltaub RA, Kavanaugh A (2006) Recent developments in diet and gout. Curr Opin Rheumatol 18:193–198PubMed Lee SJ, Terkeltaub RA, Kavanaugh A (2006) Recent developments in diet and gout. Curr Opin Rheumatol 18:193–198PubMed
55.
go back to reference Milkus TR, Kenneth GS (2006) New insights into gout epidemiology. Curr Opin Rheumatol 18:199–203CrossRef Milkus TR, Kenneth GS (2006) New insights into gout epidemiology. Curr Opin Rheumatol 18:199–203CrossRef
56.
go back to reference Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363:1277–1281CrossRefPubMed Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363:1277–1281CrossRefPubMed
57.
go back to reference Loenen HM, Eshuis H, Lowik MR, Schouten EG, Hulshof KF, Odink J, Kok FJ (1990) Serum uric acid correlates in elderly men and women with special reference to body composition and dietary intake (Dutch nutrition surveillance system). J Clin Epidemiol 43:1297–1303CrossRefPubMed Loenen HM, Eshuis H, Lowik MR, Schouten EG, Hulshof KF, Odink J, Kok FJ (1990) Serum uric acid correlates in elderly men and women with special reference to body composition and dietary intake (Dutch nutrition surveillance system). J Clin Epidemiol 43:1297–1303CrossRefPubMed
58.
go back to reference Nicholls A, Scott JY (1972) Effect of weight-loss on plasma and urinary levels of uric acid. Lancet 2:1223–1224CrossRefPubMed Nicholls A, Scott JY (1972) Effect of weight-loss on plasma and urinary levels of uric acid. Lancet 2:1223–1224CrossRefPubMed
59.
go back to reference Yamashita S, Matsuzawa Y, Tokunaga K, Fujioka S, Tarui S (1986) Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet. Int J Obes 10:255–264PubMed Yamashita S, Matsuzawa Y, Tokunaga K, Fujioka S, Tarui S (1986) Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet. Int J Obes 10:255–264PubMed
60.
go back to reference Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J (2000) Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 59:539–543CrossRefPubMed Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J (2000) Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 59:539–543CrossRefPubMed
61.
go back to reference Choi HK, Atkinson K, Karlson EW, Curhan G (2005) Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 165:742–748CrossRefPubMed Choi HK, Atkinson K, Karlson EW, Curhan G (2005) Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 165:742–748CrossRefPubMed
Metadata
Title
Elderly-onset gout: a review
Authors
Francesco De Leonardis
Marcello Govoni
Matteo Colina
Marco Bruschi
Francesco Trotta
Publication date
01-11-2007
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 1/2007
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-007-0421-7

Other articles of this Issue 1/2007

Rheumatology International 1/2007 Go to the issue